Etidronic acid and calcium, sequential
Etidronic Acid And Calcium, Sequential
Risedronic Acid And Calcium, Sequential
Inflammatory ocular adverse events with the use of oral bisphosphonates
First-time use of oral bisphosphonates is associated with greater risk for uveitis and scleritis, according to a retrospective cohort study in the CMAJ.
Researchers assessed the health records of all patients who visited an ophthalmologist over 7 years. Nearly 11,000 filled their first prescription for oral bisphosphonates, while 920,000 did not have any recorded bisphosphonate use.
Bisphosphonate users had increased risks for uveitis (adjusted relative risk, 1.45) and scleritis (adjusted RR, 1.51), relative to nonusers. The authors estimate numbers needed to harm of 1100 for uveitis and 370 for scleritis.
They propose that patients may experience a surge of inflammatory mediators when they begin taking bisphosphonates, which may put them at greater risk for inflammatory eye diseases. They conclude that clinicians should "inform their patients about the signs and symptoms of scleritis and uveitis, so that prompt treatment may be sought and further complications averted."